ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck CEO's 2011 Compensation Up 41% At $13.3M

By Peter Loftus Of DOW JONES NEWSWIRES Merck & Co.'s (MRK) leader received compensation valued at $13.3 million for 2011, up 41% from the year before, reflecting his ascension to the drug maker's top post and Merck's ability to exceed certain internal performance targets. Kenneth Frazier, 57, became Merck's chief executive at the beginning of 2011 and chairman of the board in December. He was previously head of Merck's human health business. In a proxy statement filed Thursday with the U.S. Securities and Exchange Commission, Merck said certain elements of Frazier's compensation reflected growth in Merck's sales and adjusted earnings for 2011. In addition, Merck's board considered "his performance, leadership, planning and oversight during a time of continued economic, regulatory and political challenges for the healthcare industry." Earlier this year, Frazier acknowledged that Merck had a tough 2011. The company endured setbacks including negative clinical data for a once-promising heart drug, vorapaxar. Merck's full-year stock price performance lagged behind most of its large-pharmaceutical peers. But Merck of Whitehouse Station, N.J., continued to cut costs and was able to raise its dividend for the first time in seven years in 2011. Frazier said in January he was optimistic about 2012. Frazier's total compensation included: $1.5 million in salary, $3.1 million in stock awards, $3 million in option awards, $3.1 million in non-equity incentive plan compensation, and $2.6 million change in pension value and non-qualified deferred compensation earnings. In its proxy, Merck said the company exceeded internal targets for most elements of a company "scorecard" that is used partly to determine executive compensation. Merck exceeded targets for financial outcomes, customer outcomes and "internal business drivers." However, Merck didn't earn any scorecard points for "people and culture." This element of the scorecard reflects Merck's ability to create "a high-performance, sustainable culture as measured by the results of our annual employee culture survey," the proxy said. Based on results of the employee survey, "the Company failed to score any points in this category," the company said. "To earn points, some improvement over 2010 scores was required. In a year of significant transformation, restructuring and change for our employees, scores decreased slightly on the areas of focus." -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
06/24/201608:00:00Merck to Hold Second-Quarter 2016 Sales and Earnings Conference...
06/22/201611:50:00MARKET SNAPSHOT: U.S. Stocks Try To Extend Gains To 3rd Day Ahead...
06/20/201612:30:00Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase I...
06/17/201613:35:56Annual Report of Employee Stock Plans (11-k)
06/17/201613:34:56Annual Report of Employee Stock Plans (11-k)
06/17/201613:33:19Annual Report of Employee Stock Plans (11-k)
06/16/201617:08:00MARKET SNAPSHOT: Stocks Snap 5-day Losing Streak; Dow Reverses...
06/16/201616:37:00MARKET SNAPSHOT: Stocks Snap 5-day Losing Streak; Dow Reverses...
06/16/201612:44:00MARKET SNAPSHOT: U.S. Stocks Fall As Investors Worry About Brexit...
06/16/201611:09:00MARKET SNAPSHOT: U.S. Stocks Head For 6th Daily Drop Amid Global...
06/16/201610:00:00MARKET SNAPSHOT: Dow Industrials Drop 113 Points As Brexit Fears...
06/16/201608:00:00Systematic Review of 58 Publications of Real-World Use of GARDASIL®...
06/16/201606:45:00Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free & O...
06/15/201608:30:00Merck Highlights Ongoing Commitment to Fighting Infectious Diseases...
06/14/201602:00:00New Data From GAP Landmark Trial Confirm GRAZAX® Significantly...
06/13/201611:00:00New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma...
06/13/201610:30:00Merck’s Investigational Insulin Glargine, MK-1293, Met Primary E...
06/11/201611:00:00Merck & Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin...
06/09/201619:07:00Merck to Acquire Biotech Company Afferent -- Update
06/09/201618:50:00Merck to Acquire Biotech Company Afferent

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad